-
1 Comment
JW Pharmaceutical Corporation is currently in a long term uptrend where the price is trading 16.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
JW Pharmaceutical Corporation's total revenue rose by 27.0% to $145B since the same quarter in the previous year.
Its net income has increased by 70.1% to $-7B since the same quarter in the previous year.
Finally, its free cash flow fell by 65.1% to $9B since the same quarter in the previous year.
Based on the above factors, JW Pharmaceutical Corporation gets an overall score of 4/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| ISIN | KR7001062009 |
| Sector | Healthcare |
| Exchange | KO |
| CurrencyCode | KRW |
| Beta | 0.93 |
|---|---|
| Market Cap | 509B |
| Dividend Yield | 0.7% |
| PE Ratio | None |
| Target Price | None |
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 001067.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
